FOXP3 and neoplasm: Notably, the spatial co-localization of CD68+ tumor-associated macrophages (TAMs) with FOXP3+ Tregs has been strongly associated with reduced ICIs efficacy, with non-nuclear FOXP3 expression further compromising therapeutic outcomes (130).